Pharma Choice LLP

Pharma Choice LLP is a pharmaceutical exporter based in Mumbai, Maharashtra, India. Established on September 15, 2017, the company operates as a Limited Liability Partnership (LLP) under the registration number AAK-5983. The registered office is located at Shop No. 12, Ground Floor, Sairam Apartment, Mulund Sai CHS Ltd, Mhada Colony, Mulund East, Mumbai, Maharashtra, 400081, India.

The ownership structure comprises three designated partners: Ganesh Rangnath Sanap, Mangesh Rangnath Sanap, and Akshay Rao Harishchandra, all appointed on September 15, 2017. The company has a total obligation of contribution amounting to ₹600,000. As of the latest available data, Pharma Choice LLP has an annual turnover ranging between ₹2 to ₹5 crore (approximately $400,000 to $1 million). The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

Pharma Choice LLP operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing capacities and specializations are not publicly disclosed. The facilities are designed to adhere to international quality standards, ensuring the production of high-quality pharmaceutical products for export markets.

The leadership team of Pharma Choice LLP comprises three designated partners:

• Ganesh Rangnath Sanap: Designated Partner since September 15, 2017.
• Mangesh Rangnath Sanap: Designated Partner since September 15, 2017.
• Akshay Rao Harishchandra: Designated Partner since September 15, 2017.

These individuals collectively oversee the strategic direction and operations of the company, leveraging their expertise to drive growth and maintain compliance with regulatory standards.

Pharma Choice LLP's export activities are primarily focused on markets in Asia, including the Philippines. The company has engaged in the export of pharmaceutical products such as the Hepatitis B Vaccine rDNA 100mcg to the Philippines, indicating a presence in the Southeast Asian market. Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's export strategy appears to be concentrated in select Asian markets, with limited information on its presence in other regulated markets.

Pharma Choice LLP has demonstrated a presence in emerging markets, particularly in Southeast Asia. The export of the Hepatitis B Vaccine rDNA 100mcg to the Philippines suggests an engagement with the Southeast Asian pharmaceutical market. However, specific information regarding the company's activities in Africa, Latin America, and other parts of Southeast Asia is not publicly available. The company's focus on select markets indicates a strategic approach to market penetration, potentially leveraging WHO prequalification to enhance access in these regions.

Pharma Choice LLP's export strategy appears to be concentrated in select Asian markets, with a notable presence in the Philippines. The company's focus on specific regions suggests a targeted approach to market penetration, potentially to mitigate risks associated with over-diversification. However, the limited geographic diversification may expose the company to risks related to market fluctuations and regulatory changes in these regions. A more diversified geographic strategy could potentially enhance the company's resilience and growth prospects.

Specific information regarding Pharma Choice LLP's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities appear to be primarily focused on markets in Asia, with limited information on its presence in the United States. This suggests that Pharma Choice LLP may not currently have FDA approvals or registrations for its products.

There is no publicly available information indicating that Pharma Choice LLP holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export activities are primarily focused on select Asian markets, and it is unclear whether its manufacturing facilities comply with WHO or EU GMP standards. Obtaining such certifications could enhance the company's credibility and facilitate access to additional international markets.

Pharma Choice LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. Specific details regarding the company's manufacturing licenses, approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly available. The company's focus on select export markets suggests compliance with Indian regulatory requirements for pharmaceutical exports.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Pharma Choice LLP. The company's export activities appear to be primarily focused on select Asian markets, and it is unclear whether it has been subject to regulatory actions in other jurisdictions.

Pharma Choice LLP operates in a competitive landscape with numerous pharmaceutical exporters in India. While specific competitors in overlapping categories are not publicly identified, the company's focus on select Asian markets suggests competition with other exporters targeting similar regions. The company's market share in these regions is not publicly disclosed, making a direct head-to-head analysis challenging.

Pharma Choice LLP's key differentiators include its specialization in finished pharmaceutical formulations and its focus on select Asian markets. The company's product portfolio, as indicated by its export data, includes a range of pharmaceutical products across various therapeutic categories. However, specific details regarding the uniqueness of its product offerings are not publicly available.

Pharma Choice LLP's current strategic direction appears to be focused on exporting finished pharmaceutical formulations to select Asian markets. The company's limited geographic diversification suggests a targeted approach to market penetration. Future strategic directions may involve expanding its product portfolio, obtaining international certifications such as WHO prequalification and EU GMP, and exploring additional export markets to enhance growth prospects.

Pharma Choice LLP's track record in exporting pharmaceutical products is evident from its export data, which includes shipments of products like the Hepatitis B Vaccine rDNA 100mcg to the Philippines. The company's export volume and consistency are not publicly disclosed, making a comprehensive assessment of its reliability challenging. However, the company's focus on select markets suggests a strategic approach to supply chain management.

Importers should verify the following certifications when considering Pharma Choice LLP as a supplier:

• FDA Registration: To confirm compliance with U.S. regulatory standards. Verification can be done through the FDA's official website.
• WHO-GMP Certification: To ensure adherence to international manufacturing standards. Verification can be done through the WHO's official website.
• EU GMP Certification: To confirm compliance with European manufacturing standards. Verification can be done through the European Medicines Agency's official website.
• ISO Certification: To ensure quality management systems are in place. Verification can be done through the International Organization for Standardization's official website.

When conducting due diligence on Pharma Choice LLP, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.
• Assess Financial Health: Review financial statements and credit reports to evaluate financial stability.
• Evaluate Product Quality: Request product samples and conduct quality assessments.
• Check References: Contact previous clients and partners to assess reliability and performance.
• Inspect Manufacturing Facilities: If possible, conduct site visits to assess manufacturing capabilities and compliance with standards.

Red flags to watch for include expired or invalid certifications, inconsistent financial records, and negative feedback from references. Recommended pre-order checks involve confirming product availability, lead times, and shipping terms.